PL2083837T3 - Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym - Google Patents

Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym

Info

Publication number
PL2083837T3
PL2083837T3 PL07866446T PL07866446T PL2083837T3 PL 2083837 T3 PL2083837 T3 PL 2083837T3 PL 07866446 T PL07866446 T PL 07866446T PL 07866446 T PL07866446 T PL 07866446T PL 2083837 T3 PL2083837 T3 PL 2083837T3
Authority
PL
Poland
Prior art keywords
treatment
therapeutic use
antineoplastic agent
pain induced
botulic neurotoxin
Prior art date
Application number
PL07866446T
Other languages
English (en)
Inventor
Christine Favre
Michel Auguet
De Lassauniere Pierre-Etienne Chabrier
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of PL2083837T3 publication Critical patent/PL2083837T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07866446T 2006-10-27 2007-10-26 Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym PL2083837T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0609435A FR2907680B1 (fr) 2006-10-27 2006-10-27 Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
EP07866446.3A EP2083837B1 (fr) 2006-10-27 2007-10-26 Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
PCT/FR2007/001773 WO2008059126A1 (fr) 2006-10-27 2007-10-26 Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux

Publications (1)

Publication Number Publication Date
PL2083837T3 true PL2083837T3 (pl) 2015-06-30

Family

ID=38109619

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07866446T PL2083837T3 (pl) 2006-10-27 2007-10-26 Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym

Country Status (12)

Country Link
US (1) US8273359B2 (pl)
EP (1) EP2083837B1 (pl)
JP (1) JP5386359B2 (pl)
CN (1) CN101541336B (pl)
CA (1) CA2667128C (pl)
DK (1) DK2083837T3 (pl)
ES (1) ES2532850T3 (pl)
FR (1) FR2907680B1 (pl)
PL (1) PL2083837T3 (pl)
PT (1) PT2083837E (pl)
RU (1) RU2483747C2 (pl)
WO (1) WO2008059126A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
FR2889936B1 (fr) * 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
CA2667536C (en) * 2006-10-27 2016-05-03 Tokushima University Highly purified type a botulinum toxin preparation from infant botulism pathogen
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100332337A1 (en) * 2009-06-25 2010-12-30 Bullock Roddy Mckee Universal one-click online payment method and system
EP3372239B1 (en) 2012-05-30 2020-11-11 President and Fellows of Harvard College Engineered botulinum neurotoxin
EP2952205B1 (en) * 2014-06-06 2017-08-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
KR102363099B1 (ko) 2016-02-19 2022-02-15 애버리 데니슨 코포레이션 접착제를 제조하는 2단계 방법 및 관련 조성물
CN110072880B (zh) 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素
CN110099939B (zh) 2016-10-25 2022-09-06 艾利丹尼森公司 在主链中具有光引发剂基团的嵌段聚合物及其用于粘合剂组合物中的用途
JP7507088B2 (ja) 2017-12-19 2024-06-27 エイブリィ・デニソン・コーポレイション ペンダント官能基の後重合官能化
WO2021173916A1 (en) * 2020-02-27 2021-09-02 President And Fellows Of Harvard College Nociceptor neurons control cancer immunosurveillance

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159624T3 (es) * 1993-12-28 2001-10-16 Allergan Sales Inc Toxinas botulinicas para el tratamiento de la hiperhidrosis.
DE19501266A1 (de) * 1995-01-18 1996-07-25 Madaus Ag Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
EP1586329A1 (en) * 2000-02-08 2005-10-19 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
KR20030018827A (ko) 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20060178354A1 (en) * 2003-02-27 2006-08-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US20040247623A1 (en) * 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
GB2417419A (en) 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
GB2419526A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
GB2416692A (en) 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
EP1799264A2 (en) * 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain
EP1863524A1 (en) * 2005-03-03 2007-12-12 Universite Catholique De Louvain Methods and compositions for the treatment of cancer
WO2006122123A2 (en) * 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
KR100726441B1 (ko) * 2005-11-22 2007-06-11 삼성전자주식회사 현상장치 및 이를 이용한 화상형성장치
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) * 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique

Also Published As

Publication number Publication date
RU2483747C2 (ru) 2013-06-10
CN101541336B (zh) 2012-12-19
FR2907680A1 (fr) 2008-05-02
EP2083837B1 (fr) 2015-01-07
WO2008059126A1 (fr) 2008-05-22
US20100068231A1 (en) 2010-03-18
JP5386359B2 (ja) 2014-01-15
CA2667128A1 (fr) 2008-05-22
PT2083837E (pt) 2015-03-26
FR2907680B1 (fr) 2012-12-28
DK2083837T3 (en) 2015-03-23
ES2532850T3 (es) 2015-04-01
RU2009120021A (ru) 2010-12-10
CA2667128C (fr) 2017-08-29
JP2010507635A (ja) 2010-03-11
US8273359B2 (en) 2012-09-25
EP2083837A1 (fr) 2009-08-05
HK1137352A1 (en) 2010-07-30
CN101541336A (zh) 2009-09-23

Similar Documents

Publication Publication Date Title
PL2083837T3 (pl) Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym
GB0602178D0 (en) Therapeutic treatment
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
GB0625659D0 (en) Therapeutic compounds and their use
IL186616A (en) Spyro-oxa-indoles and their use as drugs
SI1978947T1 (sl) Nitrooksiderivati za uporabo pri zdravljenju mišičnih distrofij
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
IL201422A0 (en) Therapeutic agents useful for treating pain
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
SI2148667T1 (sl) Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
IL218851A0 (en) Use of dimiracetam in the treatment of chronic pain
GB0608655D0 (en) Therapeutic Treatment
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
ZA200810199B (en) Rinse-off therapeutic agents for treating skin
ZA200709542B (en) Combination therapy in the treatment of cancer
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
GB0610909D0 (en) Therapeutic treatment
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
GB0425854D0 (en) Therapeutic treatment
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
GB0408752D0 (en) Therapeutic treatment
EP1900363A4 (en) THERAPEUTIC AGENT AGAINST PAIN
GB0509911D0 (en) Medical treatment aid for use in treating children
GB0610376D0 (en) Therapeutic treatment